Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AVNS
AVNS logo

AVNS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.740
Open
24.730
VWAP
24.63
Vol
3.55M
Mkt Cap
1.15B
Low
24.550
Amount
87.50M
EV/EBITDA(TTM)
13.62
Total Shares
46.82M
EV
1.19B
EV/OCF(TTM)
32.29
P/S(TTM)
1.60
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.
Show More

Events Timeline

(ET)
2026-04-14
16:20:00
Major Averages Rise on Renewed U.S.-Iran Diplomacy Optimism
select
2026-04-14
12:00:00
Major U.S. Averages Broadly Higher, Nasdaq Up 1.66%
select
2026-04-14
06:10:00
Avanos Acquired by American Industrial Partners for Approximately $1.27B
select
2026-02-24 (ET)
2026-02-24
07:10:00
Company Reports Q4 Revenue of $180.9M
select
2026-02-24
07:10:00
Sees 2026 Revenue at $700M-$720M
select
2026-01-20 (ET)
2026-01-20
08:10:00
Avanos Medical and Siemens Healthineers Announce Strategic Co-Marketing Agreement
select
2025-11-05 (ET)
2025-11-05
11:38:10
Avanos increases FY25 adjusted EPS forecast to 85c-95c, up from 75c-95c
select

News

Globenewswire
8.5
05-05Globenewswire
Investigation Alerts for Multiple Company Mergers
  • Helix Merger Investigation: Helix Energy Solutions is set to be acquired by Hornbeck Offshore Services, with Helix shareholders expected to own approximately 45% of the combined entity, raising concerns about whether the Helix Board breached fiduciary duties by failing to ensure a fair process in the transaction.
  • TopBuild Acquisition Details: TopBuild will be acquired by QXO, allowing shareholders to choose between $505 in cash or 20.2 shares of QXO stock per TopBuild share, with the deal's total consideration being approximately 45% cash and 55% stock, prompting investigations into whether the transaction offers fair value, especially as it falls below the 52-week high of $559.47.
  • Avanos Acquisition Situation: Avanos is being acquired by American Industrial Partners for $25.00 per share, amounting to an enterprise value of approximately $1.272 billion, with investigations focusing on whether the Avanos Board failed to conduct a fair process to ensure shareholder value in the deal.
  • Affinity Bancshares Transaction: Affinity Bancshares will be acquired by Fidelity for $23.00 per share, representing a total transaction value of approximately $142.8 million, with investigations examining whether the Board breached fiduciary duties by not ensuring the fairness of the transaction for shareholders.
Globenewswire
8.5
05-05Globenewswire
Class Action Developments for Multiple Companies' Shareholders
  • XOMA Shareholder Payout: XOMA Royalty Corporation is set to be sold to Ligand Pharmaceuticals for $39.00 per share in cash, which is expected to provide substantial returns for shareholders and enhance its market appeal.
  • RE/MAX Shareholder Options: Shareholders of RE/MAX Holdings, Inc. will have the choice of receiving either 5.152 shares of the combined company or $13.80 in cash per share, which will strengthen its competitive position in the real estate market.
  • Galera Merger Shares: Following the merger with Obsidian Therapeutics, Inc., Galera Therapeutics, Inc. shareholders will own approximately 1.8% of the combined company, indicating its potential for integration in the biotechnology sector.
  • Avanos Cash Return: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, which is expected to provide direct cash returns to shareholders and enhance its financial stability.
seekingalpha
9.5
05-05seekingalpha
Avanos Medical Reports Strong Q1 2026 Earnings with Revenue Growth
  • Significant Revenue Growth: Avanos Medical reported Q1 2026 revenue of $182.2 million, an 8.8% year-over-year increase that exceeded market expectations by $12.2 million, indicating strong performance in the medical device sector.
  • Strong Specialty Nutrition Systems Performance: The Specialty Nutrition Systems (SNS) segment achieved net sales of $124.0 million, a $22.9 million increase from the prior year, reflecting the segment's continued competitive strength in the market.
  • Stable Pain Management and Recovery Segment: The Pain Management and Recovery (PM&R) segment reported net sales of $56.3 million, remaining flat compared to the previous year, which provides a stable foundation for future growth despite the lack of growth in this area.
  • 2026 Sales Outlook: Avanos expects sales in 2026 to range between $700 million and $720 million, primarily benefiting from tariff mitigation following its exit from the Chinese market, showcasing the company's positive outlook on future market conditions.
Globenewswire
8.5
04-24Globenewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Merger Investigation: Halper Sadeh LLC is investigating Helix Energy Solutions Group, Inc. (NYSE: HLX) for its merger with Hornbeck Offshore Services, Inc., where Helix shareholders will own approximately 45% of the combined company, potentially impacting shareholder rights and future earnings.
  • Cash and Stock Options: TopBuild Corp. (NYSE: BLD) is set to be sold to QXO, Inc., allowing shareholders to choose between receiving $505.00 in cash or 20.2 shares of QXO common stock for each TopBuild share, which may influence shareholder returns and decision-making.
  • Acquisition Price Confirmation: Avanos Medical, Inc. (NYSE: AVNS) is being sold to affiliates of American Industrial Partners for $25.00 per share in cash, and shareholders need to assess whether this price is fair and its implications for the company's future.
  • Shareholder Rights Protection: Affinity Bancshares, Inc. (NASDAQ: AFBI) plans to sell to Fidelity BancShares (N.C.) for $23.00 per share in cash, with the price subject to adjustment based on adjusted stockholders' equity, prompting shareholders to actively understand their legal rights and options.
PRnewswire
8.5
04-23PRnewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Investigation Background: Halper Sadeh LLC is investigating companies including Whitestone REIT, Soleno Therapeutics, Odyssey Marine Exploration, and Avanos Medical for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
  • Whitestone REIT Transaction: Whitestone REIT is being sold to Ares Management Corporation for $19.00 per share, and Halper Sadeh LLC may seek to increase the consideration to ensure shareholders receive fair compensation.
  • Soleno Therapeutics Transaction: Soleno Therapeutics, Inc. is being sold for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to understand their legal rights, potentially requesting additional disclosures to protect shareholder interests.
  • Avanos Medical Transaction: Avanos Medical, Inc. is being sold to affiliates of American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may advocate for higher consideration and other remedies for shareholders.
Globenewswire
7.0
04-23Globenewswire
Investor Rights Law Firm Investigates Multiple Companies
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating the sale of Leggett & Platt, Incorporated, where shareholders will receive 0.1455 shares of Somnigroup common stock for each share of Leggett & Platt, resulting in approximately 9% ownership in the combined company, potentially impacting shareholder rights and future earnings.
  • Cash Acquisition Details: Avanos Medical, Inc. is being sold to American Industrial Partners for $25.00 per share in cash, prompting shareholders to consider the implications of this transaction on their investments and rights.
  • Select Medical Holdings Transaction: Select Medical Holdings Corporation is set to be sold for $16.50 per share in cash to a consortium led by its executives and directors, urging shareholders to understand the potential impacts of this deal and their legal options.
  • Merger Transaction Analysis: The merger between Galera Therapeutics, Inc. and Obsidian Therapeutics, Inc. is expected to result in Galera shareholders owning approximately 1.8% of the combined company, necessitating attention to changes in shareholder rights and potential financial impacts post-merger.

Valuation Metrics

The current forward P/E ratio for Avanos Medical Inc (AVNS.N) is 30.67, compared to its 5-year average forward P/E of 16.92. For a more detailed relative valuation and DCF analysis to assess Avanos Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
16.92
Current PE
30.67
Overvalued PE
22.24
Undervalued PE
11.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.03
Current EV/EBITDA
15.52
Overvalued EV/EBITDA
16.58
Undervalued EV/EBITDA
-2.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.41
Current PS
1.57
Overvalued PS
1.85
Undervalued PS
0.96

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of stocks to daytrade
Intellectia · 53 candidates
Market Cap: >= 50.00MPrice: $2.00 - $100.00New High Low: 52w_High, 52w_LowList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
WULF logo
WULF
Terawulf Inc
8.25B
AVNS logo
AVNS
Avanos Medical Inc
675.76M
CAG logo
CAG
Conagra Brands Inc
6.94B
HST logo
HST
Host Hotels and Resorts, Inc
13.93B
ASX logo
ASX
ASE Technology Holding Co Ltd
59.12B
APLS logo
APLS
Apellis Pharmaceuticals Inc
5.22B
Stocks Bullish Tomorrow
Intellectia · 75 candidates
Moving Average Relationship: PriceAboveMA20Option Sentiments: BullishOne Day Rise Prob: >= 60One Day Predict Return: >= 1.0%Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
EHAB logo
EHAB
Enhabit Inc
554.91M
FET logo
FET
Forum Energy Technologies Inc
526.00M
BLFY logo
BLFY
Blue Foundry Bancorp
293.98M
GSBC logo
GSBC
Great Southern Bancorp Inc
704.33M
GORO logo
GORO
Gold Resource Corp
242.79M
AVNS logo
AVNS
Avanos Medical Inc
641.97M

Whales Holding AVNS

A
Armistice Capital LLC
Holding
AVNS
+6.21%
3M Return
B
Blackhill Capital, Inc
Holding
AVNS
-2.65%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Avanos Medical Inc (AVNS) stock price today?

The current price of AVNS is 24.61 USD — it has decreased -0.36

What is Avanos Medical Inc (AVNS)'s business?

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. It offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Specialty Nutrition Systems portfolio of products includes enteral feeding, which consist of MIC-KEY enteral feeding tubes and Corpak patient feeding solutions, and Neonate solutions feeding products consist of NeoMed neonatal and pediatric feeding solutions. It also includes Nexus TKO, an anti-reflux needleless connector technology. The Pain Management and Recovery is a portfolio of non-opioid pain solutions including surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems, as well as Radiofrequency Ablation solutions, which provide invasive pain relief therapies, such as COOLIEF, Trident and ESSENTEC RFA products.

What is the price predicton of AVNS Stock?

Wall Street analysts forecast AVNS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVNS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Avanos Medical Inc (AVNS)'s revenue for the last quarter?

Avanos Medical Inc revenue for the last quarter amounts to 182.20M USD, increased 8.78

What is Avanos Medical Inc (AVNS)'s earnings per share (EPS) for the last quarter?

Avanos Medical Inc. EPS for the last quarter amounts to 0.11 USD, decreased -21.43

How many employees does Avanos Medical Inc (AVNS). have?

Avanos Medical Inc (AVNS) has 2287 emplpoyees as of May 23 2026.

What is Avanos Medical Inc (AVNS) market cap?

Today AVNS has the market capitalization of 1.15B USD.